Dear Investor,

It’s rare to find Market Leaders in a growing industry with huge scalability at almost single digit PE and that too in essential-products industries.  

It normally happens when the company or the industry have had a few rough years or the investor’s perception about the industry or the company is that of commodity business.

Well, as investors our job is to unearth such companies, do a proper due-diligence, see if the company’s nature of business is truly commodity or if it has branding power (supported by 5-10 years’ performance), is diversifying and is on the growth path. If it is, then there’s no reason to not invest at such low valuations well before the other investors join the bandwagon.

Because by the time they do, the early investors would have already witnessed the benefit of both the earnings compounding and re-rating of valuations.

Just yesterday, we released our New Stock Recommendation for long term investment for our Premium Members and it is based on the same logic as described above.

We come out with 5-6 new stock ideas for long-medium term investment every year and would like to share with you details on the latest one.

Basic Details:

  • Segment – Essential Products
  • Market Cap – < 5,000 crore
  • Enterprise Value – < 5,000 crore
  • Promoter Holding – > 50%
  • Increase in Promoter Holding in the last 3 Years – Yes
  • FY 10 – 9M FY 21 Sales Growth – > 14% CAGR
  • FY 10 – 9M FY 21 Operating Profit Growth – > 17% CAGR
  • FY 10 – 9M FY 21 PBT Growth – > 20% CAGR
  • Debt – Reduced in the last 5 years on both absolute and relative basis 

Key Reasons as to why we like the company: 

  • Company deals in essential products and its business was largely unaffected even during the first phase of the lock-down
  • Company’s sales are well diversified geographically; thus, problems in one country/region (say India) do not impact the business significantly
  • Company is diversifying revenue base with the launch of new products, which have higher growth and margin potential
  • Over the last 5-6 years the balance sheet of the company has improved significantly
  • Company has increased the dividend pay-out ratio by 4-5x
  • With the expected improvement in margins, we expect the company to record 17%-20% CAGR in earnings over the next 3 years
  • Last, but not the least, despite a decent track record, expectation of a 17%-20% year on year growth and improving balance sheet, the stock is still trading at less than 10 times pre-tax earnings 

Thus, considering very low valuations, market leadership and very good potential for growth, we believe the stock is offering a good investment opportunity around current level. We have also added the stock in our Model Portfolio.    

 

Best Regards,

Ekansh Mittal
Research Analyst 
Web: https://www.katalystwealth.com/

 

SEBI Research Analyst Registration No. INH100001690

Research Analyst Details

Name: Ekansh Mittal     Email Id: [email protected]    Ph: +91 727 5050062

Details of Associate: Not Applicable

Analyst Certification: The Analyst certify (ies) that the views expressed herein accurately reflect his (their) personal view(s) about the subject security (ies) and issuer(s) and that no part of his (their) compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report.

Disclaimer: www.katalystwealth.com (here in referred to as Katalyst Wealth) is the domain owned by Ekansh Mittal. Mr. Ekansh Mittal is the sole proprietor of Mittal Consulting and offers independent equity research services to investors on subscription basis. SEBI (Research Analyst) Regulations 2014, Registration No. INH100001690

The views expressed are based solely on information available publicly and believed to be true. Investors are advised to independently evaluate the market conditions/risks involved before making any investment decision

A graph of daily closing prices of securities is available at www.bseindia.com (Choose a company from the list on the browser and select the “three years” period in the price chart

This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. Ekansh Mittal/Mittal Consulting/Katalyst Wealth is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your information and should not be reproduced or redistributed to any other person in any form. This document is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Ekansh Mittal or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Neither Ekansh Mittal, nor its employees, agents nor representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. Ekansh Mittal/Mittal Consulting or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement.

The recipients of this report should rely on their own investigations. Ekansh Mittal/Mittal Consulting and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Mittal Consulting has incorporated adequate disclosures in this document. This should, however, not be treated as endorsement of the views expressed in the report.

We submit that no material disciplinary action has been taken on Ekansh Mittal by any regulatory authority impacting Equity Research Analysis.

Disclosure (SEBI RA Regulations)

Whether the research analyst or research entity or his associate or his relative has any financial interest in the subject company/companies and the nature of such financial interest – No

Whether the research analyst or research entity or his associates or his relatives have actual/beneficial ownership of 1% or more securities of the subject company (at the end of the month immediately preceding the date of publication of the research report or date of the public appearance) – No

Whether the research analyst or research entity or his associate or his relative has any other material conflict of interest at the time of publication of the research report or at the time of public appearance – No

Whether it or its associates have received any compensation from the subject company in the past twelve months – No

Whether it or its associates have managed or co-managed public offering of securities for the subject company in the past 12 months – No

Whether it or its associates have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months – No

Whether it or its associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months – No

Whether the subject company is or was a client during twelve months preceding the date of distribution of the research report and the types of services provided – No

Whether the research analyst has served as an officer, director or employee of the subject company – No

Whether the research analyst or research entity has been engaged in market making activity for the subject company – No